Enhancing chemosensitivity in pancreatic cancer: Novel strategies to overcome therapeutic resistance

作者：Wenhao Luo, Menggang Zhang, Hao Chen, Jun Wang, Zhe Cao, Gang Yang, Jiangdong Qiu, Yueze Liu, Yifan Fu, Jinxin Tao, Guihu Weng, Tao Liu, Yueyang Wang, Liyuan Ye, Chen Ding, Xiaoyue Lu, Yi Dong, Zeyu Zhang, Shijuan Jiang, Chenguang Du, Bidong Fu, Hua Huang, Jianchun Xiao, Lei You, Taiping Zhang · 发表于：Oncology and Translational Medicine · 年份：2025 · DOI：10.1097/ot9.0000000000000098 · 被引用次数：6 · 研究领域：Pancreatic and Hepatic Oncology Research、Cancer Cells and Metastasis、Cancer Genomics and Diagnostics

Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and fatal malignancies, with a 5-year survival rate of <15%. Despite significant advancements in targeted therapies and immunotherapy, these approaches benefit only a limited subset of patients, leaving chemotherapy as the primary treatment modality for most patients. Chemotherapy is an essential adjunct to surgical resection, the only potentially curative option, playing a crucial role in reducing the tumor burden, delaying disease progression, and alleviating symptoms. However, its long-term efficacy is frequently undermined by the development of chemoresistance, wherein tumor cells adopt diverse strategies to evade or repair chemotherapy-induced damage. Addressing this critical barrier is imperative for improving the clinical outcomes of PDAC. This review comprehensively examines the multifaceted mechanisms of chemoresistance in PDAC and highlights innovative strategies designed to enhance chemosensitivity, thereby offering new hope for overcoming these challenges and improving patient survival.